GB2420781B - Aminopyrones and their use as ATM inhibitors - Google Patents

Aminopyrones and their use as ATM inhibitors

Info

Publication number
GB2420781B
GB2420781B GB0604321A GB0604321A GB2420781B GB 2420781 B GB2420781 B GB 2420781B GB 0604321 A GB0604321 A GB 0604321A GB 0604321 A GB0604321 A GB 0604321A GB 2420781 B GB2420781 B GB 2420781B
Authority
GB
United Kingdom
Prior art keywords
group
optionally substituted
aminopyrones
atm inhibitors
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0604321A
Other languages
English (en)
Other versions
GB0604321D0 (en
GB2420781A (en
Inventor
Graeme Cameron Murray Smith
Niall Morrison Barr Martin
Xiao-Ling Fan Cockcroft
Ian Timothy Williams Matthews
Keith Allan Menear
Laurent Jean Martin Rigoreau
Marc Geoffrey Hummersone
Roger John Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kudos Pharmaceuticals Ltd
Original Assignee
Kudos Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kudos Pharmaceuticals Ltd filed Critical Kudos Pharmaceuticals Ltd
Publication of GB0604321D0 publication Critical patent/GB0604321D0/en
Publication of GB2420781A publication Critical patent/GB2420781A/en
Application granted granted Critical
Publication of GB2420781B publication Critical patent/GB2420781B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GB0604321A 2003-08-13 2004-08-13 Aminopyrones and their use as ATM inhibitors Expired - Fee Related GB2420781B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49477603P 2003-08-13 2003-08-13
PCT/GB2004/003507 WO2005016919A1 (en) 2003-08-13 2004-08-13 Aminopyrones and their use as atm inhibitors

Publications (3)

Publication Number Publication Date
GB0604321D0 GB0604321D0 (en) 2006-04-12
GB2420781A GB2420781A (en) 2006-06-07
GB2420781B true GB2420781B (en) 2008-07-09

Family

ID=34193236

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0604321A Expired - Fee Related GB2420781B (en) 2003-08-13 2004-08-13 Aminopyrones and their use as ATM inhibitors

Country Status (19)

Country Link
US (2) US7429660B2 (de)
EP (1) EP1654257B1 (de)
JP (1) JP2007501836A (de)
KR (1) KR20060066722A (de)
CN (1) CN1867566B (de)
AT (1) ATE461193T1 (de)
AU (1) AU2004265149A1 (de)
BR (1) BRPI0413467A (de)
CA (1) CA2534300A1 (de)
DE (1) DE602004026071D1 (de)
ES (1) ES2341342T3 (de)
GB (1) GB2420781B (de)
HK (1) HK1097273A1 (de)
MX (1) MXPA06001599A (de)
NO (1) NO20061126L (de)
NZ (1) NZ545919A (de)
TW (1) TW200524924A (de)
WO (1) WO2005016919A1 (de)
ZA (1) ZA200601595B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
DE602004026071D1 (de) * 2003-08-13 2010-04-29 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
UA88329C2 (en) 2004-09-20 2009-10-12 Кудос Фармасьютикалз Лимитед Dna-pk inhibitors
US7642254B2 (en) * 2005-02-09 2010-01-05 Kudos Pharmaceuticals Limited ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
US20070049588A1 (en) * 2005-08-31 2007-03-01 Kudos Pharmaceuticals Limited Atm inhibitor
WO2007075655A2 (en) 2005-12-19 2007-07-05 Northwestern University Compositions and methods for altering rnai
US20080279866A1 (en) * 2006-08-25 2008-11-13 The Brigham And Women's Hospital, Inc. Induction of immunosuppression by inhibition of ATM
US9101671B2 (en) 2007-01-03 2015-08-11 Sanford-Burnham Medical Research Institute Methods and compositions related to clot binding compounds
WO2008080398A1 (en) * 2007-01-05 2008-07-10 Bkg Pharma Aps Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
JP2013515008A (ja) 2009-12-18 2013-05-02 サンフォード−バーナム メディカル リサーチ インスティテュート 凝血塊結合化合物に関連する方法および組成物
WO2013003112A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
EP2758403B1 (de) 2011-09-21 2016-04-27 Inception Orion, Inc. Tricyclische verbindungen als neurogene wirkstoffe und neuroprotektiva
JP6074043B2 (ja) * 2013-08-29 2017-02-01 富士フイルム株式会社 新規なモルホリン誘導体またはその塩
KR20160049435A (ko) 2014-10-27 2016-05-09 삼성전자주식회사 Atm 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
CN110312717B (zh) * 2017-02-27 2022-04-12 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
CN109045042A (zh) * 2018-09-21 2018-12-21 上海交通大学医学院附属上海儿童医学中心 Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用
US20200355997A1 (en) * 2019-05-08 2020-11-12 Facebook Technologies, Llc Thianthrene derivatized monomers and polymers for volume bragg gratings
US11718580B2 (en) 2019-05-08 2023-08-08 Meta Platforms Technologies, Llc Fluorene derivatized monomers and polymers for volume Bragg gratings
US11780819B2 (en) 2019-11-27 2023-10-10 Meta Platforms Technologies, Llc Aromatic substituted alkane-core monomers and polymers thereof for volume Bragg gratings
EP4171651A1 (de) 2020-06-24 2023-05-03 AstraZeneca UK Limited Kombination aus antikörper-wirkstoff-konjugat und atm-inhibitor
US11879024B1 (en) 2020-07-14 2024-01-23 Meta Platforms Technologies, Llc Soft mold formulations for surface relief grating fabrication with imprinting lithography

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070726A1 (en) * 2002-02-25 2003-08-28 Kudos Pharmaceuticals Ltd Pyranones useful as atm inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (de) 1969-05-14 1973-01-17
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
AU634994B2 (en) 1988-12-21 1993-03-11 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
EP0525123B1 (de) 1990-06-20 1997-09-17 PHARMACIA & UPJOHN COMPANY Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
KR920702353A (ko) 1990-06-29 1992-09-03 로버트 에이. 아미테이지 아테롬성 동맥경화증 및 혈전등 치료제인 2-아미노-6-페닐-4h-피란-4-온
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
EP0610519B1 (de) 1992-09-02 1999-12-01 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv-medikament
DE69427907T2 (de) * 1993-04-09 2002-04-04 Toyama Chemical Co. Ltd., Tokio/Tokyo Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
AU1461197A (en) 1995-11-16 1997-06-05 Icos Corporation Cell cycle checkpoint pik-related kinase materials and methods
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
WO1998055602A1 (en) 1997-06-06 1998-12-10 Mayo Foundation For Medical Education And Research Screening for phosphatidylinositol related-kinase inhibitors
WO1998056391A1 (en) 1997-06-13 1998-12-17 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
PT1257537E (pt) 2000-01-24 2007-08-03 Astrazeneca Ab Compostos terapêuticos morfolino-substituídos.
AU2001271639A1 (en) * 2000-06-28 2002-01-08 Teva Pharmaceutical Industries Ltd. Carvedilol
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
EP1501822B1 (de) * 2002-04-30 2010-12-15 Kudos Pharmaceuticals Limited Phthalazinonderivate
DE602004026071D1 (de) * 2003-08-13 2010-04-29 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
UA88329C2 (en) * 2004-09-20 2009-10-12 Кудос Фармасьютикалз Лимитед Dna-pk inhibitors
US7642254B2 (en) 2005-02-09 2010-01-05 Kudos Pharmaceuticals Limited ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070726A1 (en) * 2002-02-25 2003-08-28 Kudos Pharmaceuticals Ltd Pyranones useful as atm inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chiosis G et al, Bioorganic & Medicinal Chemistry Letters, (2001), 11(7), 909-913 *
Hollick J.J et al, Bioorganic & Medicinal Chemistry Letters, (2003), 13(18), 3083-3086 *

Also Published As

Publication number Publication date
ES2341342T3 (es) 2010-06-18
CA2534300A1 (en) 2005-02-24
ATE461193T1 (de) 2010-04-15
US20090043091A1 (en) 2009-02-12
WO2005016919A1 (en) 2005-02-24
EP1654257A1 (de) 2006-05-10
MXPA06001599A (es) 2006-05-19
TW200524924A (en) 2005-08-01
US7429660B2 (en) 2008-09-30
DE602004026071D1 (de) 2010-04-29
CN1867566A (zh) 2006-11-22
CN1867566B (zh) 2010-06-16
BRPI0413467A (pt) 2006-10-17
NO20061126L (no) 2006-05-09
GB0604321D0 (en) 2006-04-12
ZA200601595B (en) 2007-03-28
AU2004265149A1 (en) 2005-02-24
KR20060066722A (ko) 2006-06-16
GB2420781A (en) 2006-06-07
NZ545919A (en) 2009-07-31
JP2007501836A (ja) 2007-02-01
US20050054657A1 (en) 2005-03-10
HK1097273A1 (en) 2007-06-22
EP1654257B1 (de) 2010-03-17

Similar Documents

Publication Publication Date Title
ZA200601595B (en) Aminopyrones and their use as ATM inhibitors
HK1069827A1 (en) Pyranones useful as atm inhibitors.
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
TW200616986A (en) DNA-pk inhibitors
DK1417196T3 (da) DNA-PK inhibitorer
TW200635895A (en) PARP inhibitors
NO20020305D0 (no) Nye bisyklonukleosidanaloger
IN2012CN09242A (de)
TW200612920A (en) Novel imidazolidine derivatives
TW200638938A (en) ATM inhibitors
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
HUP0303457A2 (hu) Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk
GB0119863D0 (en) DNA-PK inhibitors
HUP0001009A2 (hu) Herbicid hatású 3-karbamoil/3-tiokarbamoil-szubsztituált 2-benzoil-ciklohexán-1,3-dionok, intermedierjeik, előállításuk és alkalmazásuk
TW200738679A (en) Carboxamide compound and use of the same
TR200103286T2 (tr) Projesteron reseptörü modülatörleri olarak siklokarbamat türevleri
TW200508211A (en) 2-naphthylimino-1,3-thiazine derivatives
ATE407129T1 (de) Pentafluoroalkylsulfin-naphthaline und und darauf bezogene modulatoren des östrogenrezeptors

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20110813